Cargando…

Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma

Synovial sarcoma is an aggressive malignancy that generally affects adolescents and young adults and is characterized by high rates of recurrence and metastasis, with a 10-year survival rate of about 50%. The fusion oncoprotein SS18-SSX, the product of a pathognomonic chromosomal translocation t(X;1...

Descripción completa

Detalles Bibliográficos
Autores principales: Raquib, Ainiah Rushdiana, Hofvander, Jakob, Ta, Monica, Nielsen, Torsten O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444294/
https://www.ncbi.nlm.nih.gov/pubmed/35880992
http://dx.doi.org/10.1097/PAI.0000000000001049
_version_ 1784783185349967872
author Raquib, Ainiah Rushdiana
Hofvander, Jakob
Ta, Monica
Nielsen, Torsten O.
author_facet Raquib, Ainiah Rushdiana
Hofvander, Jakob
Ta, Monica
Nielsen, Torsten O.
author_sort Raquib, Ainiah Rushdiana
collection PubMed
description Synovial sarcoma is an aggressive malignancy that generally affects adolescents and young adults and is characterized by high rates of recurrence and metastasis, with a 10-year survival rate of about 50%. The fusion oncoprotein SS18-SSX, the product of a pathognomonic chromosomal translocation t(X;18), is the oncogenic driver of this sarcoma, disrupting differentiation through widespread epigenetic dysregulation. Experimental research into SS18-SSX biology has been limited by the lack of an antibody that specifically detects the endogenous fusion oncoprotein as opposed to its native SS18 or SSX components. Recently, a rabbit monoclonal antibody was developed and made commercially available, which specifically detects the fusion junction site epitope of SS18-SSX as found in at least 95% of synovial sarcomas. Here, we characterize a suite of molecular biology assays using this new antibody, both confirming existing and reporting on novel applications. We demonstrate its high sensitivity and specificity for synovial sarcoma diagnosis on patient samples through positive immunohistochemical staining on synovial sarcoma, tissue microarray, and full face sections. In addition, we demonstrate detection of the human SS18-SSX protein when expressed in a genetically engineered mouse model of synovial sarcoma. We also demonstrate nuclear staining of SS18-SSX in synovial sarcoma cells using immunofluorescence, and visualize the interaction between SS18-SSX and the BAF complex member BRG1 through a proximity ligation assay. Lastly, we confirm the interaction between SS18-SSX and promoter regions of target genes through chromatin immunoprecipitation. This antibody represents a breakthrough in sarcoma research and has value in multiple applications to expand the knowledge of synovial sarcoma biology.
format Online
Article
Text
id pubmed-9444294
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94442942022-09-13 Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma Raquib, Ainiah Rushdiana Hofvander, Jakob Ta, Monica Nielsen, Torsten O. Appl Immunohistochem Mol Morphol Research Articles Synovial sarcoma is an aggressive malignancy that generally affects adolescents and young adults and is characterized by high rates of recurrence and metastasis, with a 10-year survival rate of about 50%. The fusion oncoprotein SS18-SSX, the product of a pathognomonic chromosomal translocation t(X;18), is the oncogenic driver of this sarcoma, disrupting differentiation through widespread epigenetic dysregulation. Experimental research into SS18-SSX biology has been limited by the lack of an antibody that specifically detects the endogenous fusion oncoprotein as opposed to its native SS18 or SSX components. Recently, a rabbit monoclonal antibody was developed and made commercially available, which specifically detects the fusion junction site epitope of SS18-SSX as found in at least 95% of synovial sarcomas. Here, we characterize a suite of molecular biology assays using this new antibody, both confirming existing and reporting on novel applications. We demonstrate its high sensitivity and specificity for synovial sarcoma diagnosis on patient samples through positive immunohistochemical staining on synovial sarcoma, tissue microarray, and full face sections. In addition, we demonstrate detection of the human SS18-SSX protein when expressed in a genetically engineered mouse model of synovial sarcoma. We also demonstrate nuclear staining of SS18-SSX in synovial sarcoma cells using immunofluorescence, and visualize the interaction between SS18-SSX and the BAF complex member BRG1 through a proximity ligation assay. Lastly, we confirm the interaction between SS18-SSX and promoter regions of target genes through chromatin immunoprecipitation. This antibody represents a breakthrough in sarcoma research and has value in multiple applications to expand the knowledge of synovial sarcoma biology. Lippincott Williams & Wilkins 2022-09 2022-07-27 /pmc/articles/PMC9444294/ /pubmed/35880992 http://dx.doi.org/10.1097/PAI.0000000000001049 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Research Articles
Raquib, Ainiah Rushdiana
Hofvander, Jakob
Ta, Monica
Nielsen, Torsten O.
Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma
title Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma
title_full Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma
title_fullStr Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma
title_full_unstemmed Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma
title_short Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma
title_sort expanding the use of an ss18-ssx antibody for molecular assays in synovial sarcoma
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444294/
https://www.ncbi.nlm.nih.gov/pubmed/35880992
http://dx.doi.org/10.1097/PAI.0000000000001049
work_keys_str_mv AT raquibainiahrushdiana expandingtheuseofanss18ssxantibodyformolecularassaysinsynovialsarcoma
AT hofvanderjakob expandingtheuseofanss18ssxantibodyformolecularassaysinsynovialsarcoma
AT tamonica expandingtheuseofanss18ssxantibodyformolecularassaysinsynovialsarcoma
AT nielsentorsteno expandingtheuseofanss18ssxantibodyformolecularassaysinsynovialsarcoma